Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
9VCDBQFmQuW06a3X
Listen
